JP2017527602A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527602A5
JP2017527602A5 JP2017515074A JP2017515074A JP2017527602A5 JP 2017527602 A5 JP2017527602 A5 JP 2017527602A5 JP 2017515074 A JP2017515074 A JP 2017515074A JP 2017515074 A JP2017515074 A JP 2017515074A JP 2017527602 A5 JP2017527602 A5 JP 2017527602A5
Authority
JP
Japan
Prior art keywords
piperidine
piperidin
carboxylic acid
pyridin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017515074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527602A (ja
JP6678656B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/057219 external-priority patent/WO2016042536A1/en
Publication of JP2017527602A publication Critical patent/JP2017527602A/ja
Publication of JP2017527602A5 publication Critical patent/JP2017527602A5/ja
Priority to JP2020035272A priority Critical patent/JP6908747B2/ja
Application granted granted Critical
Publication of JP6678656B2 publication Critical patent/JP6678656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017515074A 2014-09-19 2015-09-18 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 Active JP6678656B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020035272A JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052537P 2014-09-19 2014-09-19
US62/052,537 2014-09-19
PCT/IB2015/057219 WO2016042536A1 (en) 2014-09-19 2015-09-18 Novel soluble guanylate cyclase activators and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020035272A Division JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2017527602A JP2017527602A (ja) 2017-09-21
JP2017527602A5 true JP2017527602A5 (https=) 2018-10-25
JP6678656B2 JP6678656B2 (ja) 2020-04-08

Family

ID=54238488

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017515074A Active JP6678656B2 (ja) 2014-09-19 2015-09-18 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP2020035272A Active JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP2021109106A Pending JP2021155450A (ja) 2014-09-19 2021-06-30 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020035272A Active JP6908747B2 (ja) 2014-09-19 2020-03-02 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用
JP2021109106A Pending JP2021155450A (ja) 2014-09-19 2021-06-30 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用

Country Status (21)

Country Link
US (2) US9938260B2 (https=)
EP (1) EP3194384A1 (https=)
JP (3) JP6678656B2 (https=)
KR (1) KR20170054508A (https=)
CN (1) CN106687456B (https=)
AU (1) AU2015319724B2 (https=)
BR (1) BR112017005660A2 (https=)
CA (1) CA2961745A1 (https=)
CL (1) CL2017000640A1 (https=)
CO (1) CO2017002506A2 (https=)
CR (1) CR20170102A (https=)
DO (1) DOP2017000073A (https=)
EA (1) EA033697B1 (https=)
IL (1) IL251094A0 (https=)
MA (1) MA40583A (https=)
MX (1) MX2017003621A (https=)
PE (1) PE20170937A1 (https=)
PH (1) PH12017500481A1 (https=)
SG (1) SG11201701915TA (https=)
WO (1) WO2016042536A1 (https=)
ZA (1) ZA201701835B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201606269WA (en) 2014-02-06 2016-09-29 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
PE20170937A1 (es) * 2014-09-19 2017-07-13 Glaxosmithkline Ip Dev Ltd Nuevos activadores de la guanilato ciclasa soluble y su uso
AU2015316796A1 (en) 2014-09-19 2017-03-30 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as Bub1 inhibitors
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
EP3787610A1 (en) 2018-04-30 2021-03-10 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
EP3793553A1 (en) 2018-05-15 2021-03-24 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
US20220128561A1 (en) 2019-01-17 2022-04-28 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc)
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
WO2008067127A2 (en) * 2006-11-09 2008-06-05 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
TW200938529A (en) * 2007-12-03 2009-09-16 Smithkline Beecham Corp Compounds
WO2010015653A1 (en) * 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
KR20110133034A (ko) * 2009-02-26 2011-12-09 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 시클라제 활성화제
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
JP5636296B2 (ja) 2011-01-20 2014-12-03 公益財団法人微生物化学研究会 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体
PE20170937A1 (es) * 2014-09-19 2017-07-13 Glaxosmithkline Ip Dev Ltd Nuevos activadores de la guanilato ciclasa soluble y su uso

Similar Documents

Publication Publication Date Title
JP2017527602A5 (https=)
JP2016525076A5 (https=)
MX2025010774A (es) Formas en estado solido
JP2019528307A5 (https=)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2019505594A5 (https=)
JP2018519323A5 (https=)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2017502940A5 (https=)
JP2003521537A5 (https=)
JP2016520131A5 (https=)
JP2019535672A5 (https=)
JP2013510125A5 (https=)
JP2017528487A5 (https=)
JP2016538313A5 (https=)
JP2016514719A5 (https=)
JP2017504611A5 (https=)
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
JP2015508749A5 (https=)
JP2014511891A5 (https=)
JP2013540823A5 (https=)
JP2009515814A5 (https=)
JP2015524472A5 (https=)
FI3555076T3 (fi) Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja